HPV DNA Vaccine Via Electroporation for HPV16 Positive Cervical Neoplasia
NCT04131413
This study is recruiting at 2 US sites in 2 states, according to its ClinicalTrials.gov record last updated .
Summary
The primary goal of this phase I open label study is to determine the safety and tolerability of pNGVL4aCRTE6E7L2 DNA vaccine, as administered by intramuscular (IM) injection with TriGrid™ electroporation to both HIV- or HIV+ adult female subjects (≥ 19 years), with biopsy confirmed cervical intraepithelial (CIN) II or III that is human papillomavirus (HPV) 16+.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Human Papillomavirus Type 16
- Cervical Intraepithelial Neoplasia Grade II
- Cervical Intraepithelial Neoplasia, Grade III
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 19 years and older
- Sex
- Female
- Healthy volunteers
- Accepted
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Last updated on ClinicalTrials.gov
- July 2, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Alabama · 1
- University of Alabama at Birmingham · Birmingham, AL
Maryland · 1
- Johns Hopkins University · Baltimore, MD
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.